Boston Scientific Sees Significant Decline in Short Interest (BSX)
Boston Scientific (NYSE:BSX) saw a significant drop in short interest in May. As of May 30th, there was short interest totalling 20,214,310 shares, a drop of 11.0% from the May 15th total of 22,700,471 shares, Analyst Ratings Network.com reports. Based on an average trading volume of 10,811,012 shares, the days-to-cover ratio is currently 1.9 days. Approximately 1.5% of the shares of the company are short sold.
In other Boston Scientific news, EVP Michael P. Phalen unloaded 13,500 shares of Boston Scientific stock on the open market in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $13.02, for a total transaction of $175,770.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Several analysts have recently commented on the stock. Analysts at Morgan Stanley initiated coverage on shares of Boston Scientific in a research note on Tuesday, June 10th. They set an “overweight” rating and a $15.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Boston Scientific in a research note on Friday, May 30th. They now have a $14.00 price target on the stock. Finally, analysts at TheStreet upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Thursday, May 1st. Six investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $14.05.
Shares of Boston Scientific (NYSE:BSX) opened at 12.58 on Wednesday. Boston Scientific has a 1-year low of $9.02 and a 1-year high of $14.08. The stock’s 50-day moving average is $12.83 and its 200-day moving average is $12.90. The company has a market cap of $16.639 billion and a P/E ratio of 46.23.
Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by $0.02. The company had revenue of $1.77 billion for the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter in the previous year, the company posted $0.16 earnings per share. The company’s revenue for the quarter was up .7% on a year-over-year basis. Analysts expect that Boston Scientific will post $0.80 EPS for the current fiscal year.
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.